{"type":"trials","record":{"id":41742,"source_id":"clinicaltrials-gov","external_id":"NCT04935411","title":"Russian Registry of Patients With nAMD","brief_summary":"A three-year, non-randomized, observational, multicenter prospective nAMD study - patient registry.","overall_status":"Terminated","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":2665,"countries":["Russia"],"start_date":"2020-12-20","completion_date":"2022-12-05","last_update_date":"2025-08-07","source_url":"https://clinicaltrials.gov/study/NCT04935411","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Novartis","interventions":["nAMD"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of patients by gender — Baseline","Age at the diagnosis — Baseline","Percentage of patients with comorbidities and concomitant procedures and medications — Baseline","Patients with unilateral or bilateral disease — Baseline","Time from diagnosis to entry to the registry — Baseline","Social Characteristics (Working and Disability status) — Baseline","Visual acuity — Baseline, up to 2 years","Presence of edema and/or neuroepithelium detachment and/or pigment epithelium detachment — Baseline, Up to 2 years","Presence of macular atrophy — Baseline, Up to 2 years","Central retinal thickness — Baseline, Up to 2 years","Fluid type — Baseline, Up to 2 years","Indication for intravitreal anti-VEGF therapy — Baseline, Up to 2 years","Type of prescribed therapy — Up to 2 years","Percentage of patients with prescription of anti-VEGF drugs — Up to 2 years","Time from diagnosis to the therapy initiation — Up to 2 years","Time from diagnosis to anti-VEGF injection — Up to 2 years","Number of visits per year — Up to 2 years","Number of anti-VEGF injections per year — Up to 2 years","Number of Optical coherence tomography (OCTs) done per year — Up to 2 years","Rate of treatment discontinuation — Up to 2 years"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration","nAMD"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04935411","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-12-20 to 2022-12-05","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.863Z","intervention":["nAMD"],"participants":2665,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of patients by gender — Baseline","Age at the diagnosis — Baseline","Percentage of patients with comorbidities and concomitant procedures and medications — Baseline","Patients with unilateral or bilateral disease — Baseline","Time from diagnosis to entry to the registry — Baseline","Social Characteristics (Working and Disability status) — Baseline","Visual acuity — Baseline, up to 2 years","Presence of edema and/or neuroepithelium detachment and/or pigment epithelium detachment — Baseline, Up to 2 years","Presence of macular atrophy — Baseline, Up to 2 years","Central retinal thickness — Baseline, Up to 2 years","Fluid type — Baseline, Up to 2 years","Indication for intravitreal anti-VEGF therapy — Baseline, Up to 2 years","Type of prescribed therapy — Up to 2 years","Percentage of patients with prescription of anti-VEGF drugs — Up to 2 years","Time from diagnosis to the therapy initiation — Up to 2 years","Time from diagnosis to anti-VEGF injection — Up to 2 years","Number of visits per year — Up to 2 years","Number of anti-VEGF injections per year — Up to 2 years","Number of Optical coherence tomography (OCTs) done per year — Up to 2 years","Rate of treatment discontinuation — Up to 2 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41742","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}